第一财经·2025-05-07 13:12Core Viewpoint - In Q1 2025, Novo Nordisk's semaglutide surpassed Merck's Keytruda in global sales, temporarily claiming the title of "King of Drugs" with a sales figure of approximately $7.864 billion, marking a year-on-year growth of 32.17% [2][3]. Group 1: Sales Performance - In Q1 2025, semaglutide achieved global sales of 55.776 billion Danish Krone (approximately $7.864 billion), accounting for about 71% of Novo Nordisk's total revenue [2]. - Semaglutide's sales outperformed Keytruda by $664 million in Q1 2025, with Keytruda generating $7.2 billion in the same period, reflecting a year-on-year growth of 4% [3][4]. Group 2: Product Breakdown - The sales breakdown for semaglutide in Q1 2025 includes: - Ozempic (injectable version) at 32.721 billion Danish Krone (approximately $4.613 billion), a year-on-year increase of 15% [5]. - Rybelsus (oral version) at 5.695 billion Danish Krone (approximately $803 million), a year-on-year increase of 13% [5]. - Wegovy (weight loss version) at 17.36 billion Danish Krone (approximately $2.448 billion), a significant year-on-year increase of 83% [5]. Group 3: Market Dynamics - Novo Nordisk faces increasing competition from Eli Lilly's dual agonist tirzepatide, which has a cumulative sales figure of $6.15 billion across its indications, although semaglutide still leads in total sales [5]. - Eli Lilly holds a 53.3% share of the U.S. GLP-1 market in terms of total prescriptions, indicating a competitive landscape for semaglutide [6]. Group 4: Company Outlook - Novo Nordisk has revised its full-year sales growth forecast for 2025 from an initial estimate of 16% to 24% down to 13% to 21%, alongside a reduction in operating profit expectations from 19% to 27% to 16% to 24% [6].